^
    Back
    Association details:
    Biomarker:CCDC6-RET fusion
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Thyroid
    Title:

    Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma

    Published date:
    04/16/2020
    Excerpt:
    This clinically significant response achieved with LOXO-292 in a patient with a CCDC6-RET fusion-positive ATC…
    DOI:
    10.1089/thy.2019.0477